Biorow Life Sciences Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
as on 22-12-2024
- Paid Up Capital ₹ 0.50 M
as on 22-12-2024
- Company Age 11 Year, 9 Months
- Last Filing with ROC 31 Mar 2021
- Open Charges ₹ 1.50 Cr
as on 22-12-2024
- Satisfied Charges ₹ 5.00 M
as on 22-12-2024
- Revenue 0.36%
(FY 2021)
- Profit 3.06%
(FY 2021)
- Ebitda -7.73%
(FY 2021)
- Net Worth 9.84%
(FY 2021)
- Total Assets 8.79%
(FY 2021)
About Biorow Life Sciences
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2021. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.50 M.
The company currently has active open charges totaling ₹1.50 Cr. The company has closed loans amounting to ₹5.00 M, as per Ministry of Corporate Affairs (MCA) records.
Shivali Garg, Roopa Gupta, Anil Sharma, and One other member serve as directors at the Company.
- CIN/LLPIN
U24297KA2013PLC068236
- Company No.
068236
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
20 Mar 2013
- Date of AGM
30 Nov 2021
- Date of Balance Sheet
31 Mar 2021
- Listing Status
Unlisted
- ROC Code
Roc Bangalore
Industry
Company Details
- Location
Bangaluru, Karnataka, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Biorow Life Sciences?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Shivali Garg  | Director | 20-Mar-2013 | Current |
| Roopa Gupta | Additional Director | 13-May-2014 | Current |
| Anil Sharma | Director | 18-Apr-2022 | Current |
| Vaishali | Director | 18-Apr-2022 | Current |
Financial Performance of Biorow Life Sciences.
Biorow Life Sciences Limited, for the financial year ended 2021, experienced modest growth in revenue, with a 0.36% increase. The company also saw a slight improvement in profitability, with a 3.06% increase in profit. The company's net worth moved up by a moderate rise of 9.84%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Biorow Life Sciences?
In 2021, Biorow Life Sciences had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 26 Sep 2018 | ₹1.50 Cr | Open |
Others Creation Date: 13 Apr 2017 | ₹5.00 M | Satisfied |
How Many Employees Work at Biorow Life Sciences?
Unlock and access historical data on people associated with Biorow Life Sciences, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Biorow Life Sciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Biorow Life Sciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
